A Phase 1, Randomised, Double-blind, Placebo-Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of NP-011 in Healthy Volunteers
Latest Information Update: 07 Aug 2023
At a glance
- Drugs NP-011 (Primary)
- Indications Alcoholic hepatitis; Myocardial infarction; Non-alcoholic steatohepatitis; Ulcerative colitis
- Focus Adverse reactions
- Sponsors NEXEL
Most Recent Events
- 02 Aug 2023 Status changed from recruiting to completed.
- 28 Mar 2023 Planned End Date changed from 30 Jan 2023 to 15 May 2023.
- 26 Sep 2022 Status changed from not yet recruiting to recruiting.